Comparative Pharmacology
Head-to-head clinical analysis: BROMSITE versus OCUFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMSITE versus OCUFEN.
BROMSITE vs OCUFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromsite (bromfenac ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) 1 and 2, thereby reducing prostaglandin synthesis in ocular tissues.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation and pain.
1-2 tablets (200-400 mg) orally 3-4 times daily as needed.
1 drop of 0.03% solution in the affected eye(s) four times daily beginning 24 hours after cataract surgery.
None Documented
None Documented
Terminal elimination half-life 12–15 hours; prolonged in renal impairment (up to 30 hours).
1.2 to 2.0 hours (topical administration in ocular tissues); systemic half-life is 1.1 to 1.4 hours.
Primarily renal excretion of unchanged drug (~70%) and glucuronide conjugate (~20%); minor biliary/fecal elimination (~10%).
Urinary excretion of unchanged drug accounts for approximately 82% of a topical dose; fecal excretion is minor (<5%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID